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Postmenopausal women consistently have higher
phosphorus levels than similarly aged men. As it is known
that estradiol induces phosphaturia in rodents, we evaluated
the cross-sectional association of sex hormones with serum
phosphorus in 1346 community-living older men (mean age
76) of which 18% had moderate (stage 3) kidney disease.
Using linear regression with serum phosphorus levels as the
dependent variable, we found that for each 10pg/ml higher
total estradiol level there was a statistically significant
0.05mg/dl lower serum phosphorus when adjusted for age,
ethnicity, testosterone, sex hormone-binding globulin,
calcium, estimated glomerular filtration rate, intact
parathyroid hormone, 25(OH) vitamin D, bone mineral
density, and alkaline phosphatase. These results were similar
in individuals with or without chronic kidney disease. Serum
testosterone concentrations were also statistically signifi-
cantly associated with lower serum phosphorus levels. We
confirmed these results in an independent sample of 2555 older
men, wherein these associations were not attenuated when
adjusted for fibroblast growth factor-23 levels. Hence, our study
of community-living older men suggests that estradiol may
directly or indirectly induce phosphaturia in humans. The
mechanism responsible for the association of testosterone
with serum phosphorus remains to be determined.
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Higher serum phosphorus levels are associated with cardi-
ovascular disease and all-cause mortality, independent of
traditional cardiovascular disease risk factors in community-
living populations;1–3 associations that are evident even for
serum phosphorus levels within the normal range, and
among persons with normal kidney function.1–3 Phosphorus
induces vascular smooth muscle cells to calcify in vitro,4 and
higher serum levels are associated with arterial calcification5
and stiffness6,7 in the general population. Thus, insights into
the determinants of serum phosphorus on a population scale
may identify new pathways contributing to cardiovascular
disease. Yet, most demographical, dietary, and traditional
cardiovascular disease risk factors are not strongly associated
with serum phosphorus levels.8 Known determinants such as
severe chronic kidney disease (CKD) and primary hyperpar-
athyroidism are relatively rare on a population level. Thus,
determinants of serum phosphorus in community-living
populations remain largely unknown.
Across previous studies conducted among community-
living populations, women of postmenopausal age consis-
tently had serum phosphorus levels that are 0.15–0.30 mg/dl
higher than those of men of the same age.1,3,6–10 Treatment of
parathyroidectomized and ovariectomized rats with estradiol
results in a decrease in serum phosphorus levels and an
increase in urinary phosphorus loss.11 We hypothesized that
estradiol might regulate renal phosphorus excretion in men,
and that sex hormones may account for differences in serum
phosphorus between older men and women. Studying this
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question in a cohort of older men avoids the confounding
influences of endogenous changes in estradiol through the
menopausal transition and effects of postmenopausal hor-
mone therapy (HT). To that end, we evaluated the cross-
sectional association of sex hormone concentrations with
serum phosphorus levels among community-living older
men who participated in the Osteoporotic Fractures in Men
(MrOs) study.
RESULTS
Among the 1346 study participants from the United States
MrOs study (MrOs US), the mean age was 74±6 years
and 91% were white. The mean total estradiol level
was 22.6±8.6 pg/ml, mean total testosterone level was
406.8±171.1 ng/dl, mean serum phosphorus level was
3.2±0.4 mg/dl, and mean estimated glomerular filtration
rate (eGFR) was 76±18 ml/min per 1.73 m2. A total of 238
subjects (18%) had eGFR o60 ml/min per 1.73 m2, and 8
subjects (0.6%) had eGFR o30 ml/min per 1.73 m2.
Participants with higher serum phosphorus levels were more
likely to have diabetes mellitus, higher serum calcium, and
lower intact parathyroid hormone (PTH) levels. Men with
higher phosphorus levels also had lower total estradiol and
testosterone levels (Table 1).
Total estradiol levels were inversely correlated with serum
phosphorus in unadjusted analysis (r¼0.17, Po0.001;
Figure 1). In a model adjusted for age and race (Table 2,
model 1) each 10 pg/ml higher total estradiol level was
associated with a 0.088 mg/dl lower serum phosphorus
level. With additional adjustment for testosterone (model
2) and sex hormone-binding globulin (SHBG; model 3),
about one-third of this association was attenuated, but
despite this, total estradiol levels remained significantly
associated with lower phosphorus levels. Further adjustment
for serum calcium levels, eGFR, intact PTH, and 25(OH)
vitamin D levels had little effect on the association (model 4);
neither did adjustment for alkaline phosphatase and whole
body bone mineral density (BMD), such that in the final
adjusted model, every 10 pg/ml higher total estradiol level
was associated with a 0.053 mg/dl lower serum phosphorus
level (model 5). Results were similar when bioavailable
estradiol levels were evaluated in place of total estradiol
(Table 2). Results were also similar among participants with
or without CKD (defined as an eGFR o60 ml/min per
1.73 m2). Each 10 pg/ml higher total estradiol level was
associated with a 0.060 mg/dl lower serum phosphorus level
in persons without CKD (95% confidence interval 0.097 to
0.022), and 0.038 mg/dl lower serum phosphorus level in
Table 1 | Characteristics of MrOs US participants by serum phosphorus levels
Phosphorus (mg/dl)
P-value
o3.00 (n=524) 3.00–3.50 (n=549) 3.51–4.00 (n=231) 44.00 (n=42)
Demographics
Age (years)±s.d. 73±6 74±6 74±6 74±7 0.48
Caucasian % (n) 90% (474) 90% (495) 94% (218) 86% (36) 0.15
Medical history
Diabetes mellitus % (n) 12% (63) 15% (80) 23% (52) 38% (16) o0.001
Hypertension % (n) 42% (221) 46% (252) 43% (99) 59% (25) 0.13
Smoking % (n) 0.67
Current 3% (17) 4% (23) 3% (7) 2% (1)
Former 59% (307) 59% (322) 63% (146) 69% (29)
Dietary intake
Calcium (mg)±s.d. 805±396 808±389 783±352 732±381 0.56
Phosphorus (mg)±s.d. 1156±454 1162±479 1138±455 1098±478 0.79
Calories (kcal)±s.d. 1642±653 1626±642 1620±633 1572±642 0.90
Fat servings±s.d. 1.5±1.3 1.5±1.2 1.4±1.1 1.4±1.4 0.73
Physical examination measurements
BMI (kg/m2)a 26.5 (24.7, 29.0) 27.1 (24.8, 29.4) 27.3 (25.2, 30.0) 27.9 (24.6, 31.6) 0.09
Whole body BMD (g/cm2)±s.d. 1.16±0.12 1.17±0.13 1.17±1.13 1.17±0.14 0.78
Systolic blood pressure (mmHg)a 138 (127, 149) 138 (125, 150) 137 (124, 148) 139 (123, 153) 0.57
Blood measurements
Total estradiol (pg/ml)±s.d. 23.9±8.8 22.6±8.1 20.4±8.3 18.7±8.7 o0.001
Total testosterone (ng/dl)±s.d. 430±177 409±165 363±165 316±135 o0.001
eGFR (ml/min per 1.73m2)a 75 (65, 84) 74 (65, 84) 74 (65, 85) 72 (54, 84) 0.09
Calcium (mg/dl)±s.d. 9.3±0.4 9.3±0.4 9.4±0.4 9.5±0.4 o0.01
25(OH) vitamin D (ng/ml)±s.d. 26±8 25±8 24±8 26±8 0.22
Intact PTH (pg/ml)a 32 (25, 40) 29 (23, 37) 28 (23, 37) 26 (20, 33) o0.001
Alkaline phosphatase (U/l)a 71 (61, 87) 71 (59, 87) 72 (57, 88) 75 (63, 97) 0.36
Albumin (g/dl)±s.d. 4.3±0.3 4.3±0.2 4.3±0.3 4.3±0.3 0.58
Abbreviations: BMI, body mass index; BMD, bone mineral density; eGFR, estimated glomerular filtration rate; MrOs, Osteoporotic Fractures in Men; PTH, parathyroid hormone.
aMedian (interquartile range).
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persons with CKD (95% confidence interval 0.119 to
0.043).
Testosterone is the primary precursor of estradiol in men,
and we observed some attenuation of the association of
estradiol with serum phosphorus when the model was
adjusted for testosterone levels. Therefore, we further
explored the association of serum total testosterone with
serum phosphorus. In unadjusted analysis, total testosterone
was inversely correlated with serum phosphorus levels
(0.16, Po0.001; Figure 1). In age- and race-adjusted
models, each 200 ng/dl higher total testosterone level was
associated with 0.086 mg/dl lower serum phosphorus levels
(Table 3, model 1). Additional adjustment for estradiol
weakened, but did not abolish this association (model 2).
However when SHBG levels were included in models, the
association for testosterone was returned to a magnitude
similar to the unadjusted model (model 3). Further
adjustment for serum calcium, eGFR, intact PTH, and
25(OH) vitamin D had little effect on the testosterone
association (model 4); nor did adjustment for alkaline
phosphatase and whole body BMD have any effect (model 5).
To provide a comparison of the relative strength of
associations of various factors associated with serum
phosphorus, we compared the b coefficients per s.d. increase
for each continuous measure in our multivariable model. In
age and race adjusted models, the strength of the association
of estradiol with serum phosphorus was approximately the
same as that of testosterone and natural log transformed
intact PTH, and approximately twice as strong of that of
serum calcium and eGFR (Table 4).
Fibroblast growth factor (FGF)-23 is a novel phosphaturic
hormone, and may be influenced by estradiol. Therefore, to
investigate whether these results were reproducible in an
independent sample, and to determine whether adjustment
for FGF-23 levels may attenuate the associations, we repeated
our main analysis in MrOs Sweden participants; a sister
cohort to MrOs US participants with similar enrollment
criteria and available measurements, plus availability of FGF-
23 concentrations. The mean age of the 2555 MrOs Sweden
participants was 76±3 years, mean total estradiol was
21±8 pg/ml, mean total testosterone was 450±190 ng/dl,
mean serum phosphorus was 3.3±0.5 mg/dl, and mean
eGFR was 72±20 ml/min per 1.73 m2 (697 [27%] had eGFR
o60). FGF-23 levels were right skewed with a median level of
Table 2 | Association of estradiol levels with serum phosphorus levels in MrOs US participants
Total estradiol (per 10 pg/ml greater) Bioavailable estradiol (per 5 pg/ml greater)
b 95% CI P-value b 95% CI P-value
Unadjusted 0.089 0.115 to 0.062 o0.001 0.060 0.080 to 0.040 o0.001
Model 1 0.088 0.115 to 0.061 o0.001 0.059 0.080 to 0.038 o0.001
Model 2 0.058 0.091 to 0.025 0.001 0.031 0.056 to 0.006 0.014
Model 3 0.050 0.083 to 0.016 0.004 a
Model 4 0.050 0.082 to 0.016 0.004 0.033 0.057 to 0.009 0.008
Model 5 0.053 0.086 to 0.019 0.002 0.035 0.060 to 0.011 0.005
Abbreviations: CI, confidence interval; MrOs, Osteoporotic Fractures in Men.
Model 1: Adjusted for age, race.
Model 2: Adjusted for model 1 variables plus total testosterone in total estradiol model, or bioavailable testosterone in the bioavailable estradiol model.
Model 3: Adjusted for model 2 variables plus sex hormone-binding globulin.
Model 4: Adjusted for model 3 variables plus calcium, eGFR, intact PTH, and 25(OH) vitamin D.
Model 5: Adjusted for model 4 variables plus alkaline phosphatase and whole body BMD.
aModel excluded as sex hormone-binding globulin levels are used in the calculation of bioavailable sex hormone levels.
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Figure 1 |Distribution of serum phosphorus levels by
quartiles of estradiol and testosterone in older men (United
States Osteoporotic Fractures in Men study). Line within boxes
shows median level, borders of boxes reflect the twenty-fifth and
twenty-seventh percentile of the distribution, and border of error
bars reflect the tenth and ninetieth percentile of the distribution.
Total estradiol quartiles (in pg/ml) were o17.2 for quartile 1,
17.2–21.6 for quartile 2, 21.7–27.0 for quartile 3, and 427.0 for
quartile 4. Total testosterone quartiles (in ng/dl) were o300 for
quartile 1, 300–387 for quartile 2, 388–488 for quartile 3, and4448
for quartile 4.
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44 pg/ml (interquartile range 33–58 pg/ml). Other character-
istics of MrOs Sweden participants have been described in
detail elsewhere.12 The adjusted associations of estradiol and
testosterone levels with serum phosphorus levels in MrOs
Sweden participants were in the same direction and of similar
strength to those in MrOs US participants. Further adjust-
ment for FGF-23 levels did not materially alter the sex
hormone–serum phosphorus associations (Table 5).
DISCUSSION
We have shown that higher serum estradiol and testosterone
levels are each independently associated with lower serum
phosphorus levels in community-living older men. These
associations were reproducible in an independent cohort of
older men in Sweden and were not explained by one another,
SHBG levels, kidney function, intact PTH, 25(OH) vitamin
D, or FGF-23 levels. In conjunction with the previous reports,
this study suggests that estradiol may have phosphaturic
properties in humans. Little is known about the effects of
testosterone on phosphorus homeostasis. The inverse corre-
lation of testosterone and phosphorus levels reported in this
study may reflect enhanced deposition of phosphorus into
bone, reduced bone resorption, or previously unrecognized
effects on gastrointestinal absorption or renal excretion of
phosphorus.
Correlates of phosphorus levels in the general population
were recently evaluated in the Third National Health and
Nutrition Examination Survey (NHANES III).7 Dietary
Table 3 | Association of testosterone levels with serum phosphorus levels in MrOs US participants
Total testosterone (per 200 ng/dl greater) Bioavailable testosterone (per 100 ng/dl greater)
b 95% CI P-value b 95% CI P-value
Unadjusted 0.087 0.113 to 0.060 o0.001 0.102 0.132 to 0.072 o0.001
Model 1 0.086 0.113 to 0.059 o0.001 0.102 0.133 to 0.072 o0.001
Model 2 0.052 0.085 to 0.019 0.002 0.078 0.114 to 0.042 o0.001
Model 3 0.081 0.122 to 0.041 o0.001 a
Model 4 0.088 0.129 to 0.048 o0.001 0.083 0.119 to 0.048 o0.001
Model 5 0.084 0.125 to 0.043 o0.001 0.080 0.115 to 0.044 o0.001
Abbreviations: CI, confidence interval; MrOs, Osteoporotic Fractures in Men.
Model 1: Adjusted for age, race.
Model 2: Adjusted for model 1 variables plus total estradiol in the total testosterone model, or bioavailable estradiol in the bioavailable testosterone model.
Model 3: Adjusted for model 2 variables plus sex hormone-binding globulin.
Model 4: Adjusted for model 3 variables plus calcium, eGFR, intact PTH, and 25(OH) vitamin D.
Model 5: Adjusted for model 4 variables plus alkaline phosphatase and whole body BMD.
aModel excluded as sex hormone-binding globulin levels are used in the calculation of bioavailable sex hormone levels.
Table 4 | Age and race adjusted comparative strength of associations of continuous variables (per s.d. greater in each) with
serum phosphorus levels in MrOs US participants
b 95% CI P-value
Total estradiol (per 8.6 pg/ml greater) 0.076 0.098 to 0.052 o0.001
Bioavailable estradiol (per 5.5 pg/ml greater) 0.065 0.088 to 0.042 o0.001
Total testosterone (per 171.6 ng/dl greater) 0.074 0.097 to 0.051 o0.001
Bioavailable testosterone (per 76.2 ng/dl greater) 0.078 0.101 to 0.055 o0.001
Intact PTH (per 0.4 Ln greater [pg/ml]) 0.068 0.091 to 0.044 o0.001
Serum calcium (per 0.4mg/dl greater) 0.040 0.017 to 0.063 0.001
eGFR (per 18.1ml/min per 1.73m2 greater) 0.033 0.057 to 0.009 0.007
25(OH) vitamin D (per 8.0 ng/ml greater) 0.017 0.041 to 0.007 0.15
Dietary phosphorus (per 464.8mg per day greater) 0.005 0.028 to 0.018 0.68
Dietary calories (per 643.7 kcal per day greater) 0.006 0.030 to 0.017 0.61
Dietary fat (per 1.2 servings per day greater) 0.002 0.026 to 0.021 0.85
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; MrOs, Osteoporotic Fractures in Men; PTH, parathyroid hormone.
Table 5 | Associations of sex hormones with serum phosphorus and effect of FGF-23 adjustment in MrOs Sweden participants
Total estradiol (per 10pg/ml greater) Total testosterone (per 200 ng/dl greater)
Predictor variable b 95% CI P-value b 95% CI P-value
Adjusteda association 0.079 0.110 to 0.049 o0.001 0.049 0.078 to 0.021 o0.001
Adjusteda association plus FGF-23 0.080 0.110 to 0.049 o0.001 0.047 0.076 to 0.019 0.001
Abbreviations: CI, confidence interval; FGF, fibroblast growth factor; MrOs, Osteoporotic Fractures in Men.
aAdjusted for age, city, sex hormone-binding globulin, eGFR, calcium, intact PTH, and 25(OH) vitamin D. The estradiol model was additionally adjusted for total testosterone,
and conversely the testosterone model was additionally adjusted for total estradiol.
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variables, 25(OH) vitamin D levels, and kidney function were
not strongly associated with serum phosphorus levels, and
most of the variance in serum phosphorus remained
unexplained. Notably, women had serum phosphorus levels
that were 0.16 mg/dl higher on average than men in the
NHANES III;8 a finding reported consistently in other
community-living populations.1,3,6–10
The renal regulation of phosphorus is principally achieved
through the sodium phosphate co-transporter type IIa
(NaPi-IIa) in the proximal convoluted tubule.13–15 Recently,
Faroqui et al.11 reported that treatment of parathyroidecto-
mized and ovariectomized rats with estradiol decreased
NaPi-IIa mRNA and protein levels, resulting in lower serum
phosphorus levels and enhanced urinary phosphorus loss. To
our knowledge, no previous study has evaluated the
association of endogenous serum estradiol and phosphorus
levels in humans, but existing data support a similar effect. In
an observational study among over 4500 community-living
Italians with a wide age spectrum, men had a modest and
linear decrease in serum phosphorus level with advancing
age. Women followed a similar trajectory until age 45–54,
when there was an abrupt increase in serum phosphorus
levels and commensurate decrease in urinary phosphorus
loss, perhaps resulting from decreased endogenous estradiol
during the menopausal transition.9 In the Atherosclerosis
Risk in Communities (ARIC) study, women taking HT had
significantly lower serum phosphorus levels compared with
women not taking HT.10 Observational studies and small
randomized clinical trials have evaluated urine phosphorus
excretion with HT therapy. HT treatment resulted in lower
serum phosphorus levels and greater phosphaturia compared
with pre-treatment levels or to the placebo arm.16–19
Although estradiol has skeletal and other non-renal effects
that could affect phosphorus homeostasis, our leading
hypothesis is that the association reported in this study
resulted primarily from estradiol increasing urinary phos-
phorus excretion among older men. This hypothesis is
supported further by the observation that inverse correlation
of estradiol and phosphorus was essentially unaltered with
adjustment for alkaline phosphatase and BMD.
While evidence provided in this study and elsewhere
support the hypothesis that estradiol decreases NaPi-IIa
mRNA and protein levels, and induces phosphaturia, the
cellular mechanisms remain uncertain. Estrogen receptors
(ERs) are expressed in the proximal tubule of the rat
kidney,20 so a direct effect is possible. The majority of the
estrogen response is mediated through two ERs, ERa and
ERb. In rats, Faroqui et al.11 observed decreased NaPi-IIa
levels and phosphaturia in response to estradiol in vivo,
however, this effect was not blunted with a specific inhibitor
of ERa. No change in klotho levels (a key cofactor for FGF-23
binding) was observed with estradiol therapy in this study.
Using a 7/8 nephrectomy CKD model in rats, Carrillo-Lopez
et al.21 recently showed that estradiol increased serum FGF-
23 levels in vivo, and increased FGF-23 mRNA and protein
levels in a rat-derived osteoblast cell line in vitro. Because
FGF-23 decreases NaPi-IIa levels in the proximal tubule and
induces phosphaturia,22 this finding suggests that estradiol
may induce phosphaturia indirectly, through upregulation of
FGF-23. In our study, among the subset of 2555 MrOs
Sweden participants, statistical adjustment for FGF-23 levels
did not materially alter the associations of estradiol or
testosterone with serum phosphorus levels, arguing against
this hypothesis. Our observational study cannot definitively
elucidate the biological pathways responsible for these
associations. Possibilities that a direct effect of estradiol
may be mediated through ERb or other estrogen ligands have
not yet been investigated, to our knowledge.
Studies evaluating the effect of testosterone on renal
phosphorus homeostasis are sparse, conflicting, and often
confounded by concomitant changes in estradiol. Ralston
et al. evaluated treatment with estradiol versus estra-
diolþ testosterone for 6 months in 32 young surgically
menopausal women. Both groups had decreases in serum
phosphorus and increases in phosphaturia of similar
magnitude compared with pre-treatment baseline.23 Treat-
ment of healthy middle-aged men with goserelin decreases
both serum testosterone and estradiol, and concomitantly
increases serum phosphorus levels and decreases phospha-
turia.24 In experimental animals, some have reported effects
in the opposite direction to those observed in this study.
Orchiectomized male rats show lower serum phosphorus
levels compared with non-orchiectomized controls, and
testosterone treatment restored serum phosphorus levels.25
Several possibilities may account for the inverse correlation
between total testosterone with serum phosphorus levels in
our study. First, while adjustment for whole body BMD had
little effect on the association in our study, testosterone
increases bone formation and reduces bone resorption, which
might affect serum phosphorus levels. Second, testosterone is
the predominant precursor of estradiol in men.26,27 However,
it appears unlikely that the association of testosterone with
serum phosphorus is mediated through estradiol because
statistical adjustment for estradiol had little effect on the
association of testosterone with phosphorus in both the
MrOs US and MrOs Sweden cohorts. Last, it remains
possible that testosterone may have unrecognized effects on
renal or gastrointestinal phosphorus metabolism.
Previous studies consistently show phosphorus levels that
are approximately 0.15–0.30 mg/dl higher in older women
compared with similar aged men.1,3,6–10 In this study, we
report that each 10 pg/ml higher estradiol and 200 ng/dl
higher testosterone were independently associated with lower
serum phosphorus levels, (approximately 0.05 and 0.08 mg/
dl, respectively in MrOs US participants) in men. Although
this effect size may seem clinically insignificant, interpreta-
tion requires recognition that older men have serum estradiol
levels that are approximately fourfold higher (B15 pg/ml
greater), and serum testosterone levels that are approximately
20-fold higher (B285 ng/dl) than postmenopausal women.28
On the basis of the strengths of the observed associations,
differences in estradiol would be expected to account for
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approximately 0.09 mg/dl higher serum phosphorus level,
and differences in testosterone would account for an
additional 0.12 mg/dl higher phosphorus level in women
compared with men. Collectively, this magnitude of differ-
ence in serum phosphorus compares favorably to differences
in phosphorus levels between men and women reported in
previous studies. Future studies of both sexes and concurrent
measures of estradiol, testosterone, serum and urine phos-
phorus levels are required to determine whether differences
in sex hormones entirely account for the sex differences in
serum phosphorus levels.
Strengths of this study include its relatively large sample
size, community living and geographically diverse setting,
and availability of demographical, laboratory, and BMD
measurements in all participants. The similar design and
measurements in MrOs Sweden participants allowed us to
test reproducibility and evaluate potential mediation through
FGF-23. All phosphorus measurements were made in fasting
morning specimens, decreasing influences of diurnal varia-
tion. However, the study also has important limitations. We
lacked urinary phosphorus measurements, participants were
all older, most were Caucasian, and few had CKD. Results
may differ in younger persons, other race ethnicities or in
moderate to advanced CKD. The cross-sectional study design
did not allow evaluation of temporality.
We conclude that higher serum estradiol levels and
testosterone levels are each independently associated with
lower serum phosphorus levels in community-living older
men. These associations were not attenuated with adjustment
for FGF-23 levels. In the context of previous studies,
these data suggest that estradiol may directly or indirectly
induce phosphaturia in humans. The mechanism responsible
for the association of testosterone with serum phosphorus is
less certain, but may reflect either bone or previously
unrecognized renal or gastrointestinal effects, or conversion
to estradiol. Future studies should evaluate whether differ-
ences in sex hormones may explain why higher phosphorus
levels are consistently observed in older women compared
with men.
MATERIALS AND METHODS
Study participants
MrOs US. The primary analysis for this study evaluated
participants in the MrOs US study; an observational cohort study
designed to evaluate risk factors for fractures in older men.29,30
Between March 2000 and April 2002, 5995 men aged X65 years
were recruited from Birmingham, Alabama; Minneapolis, Minne-
sota; Palo Alto, California; Pittsburgh, Pennsylvania; Portland,
Oregon; and San Diego, California. Inclusion required ability to
walk without the assistance of another person; absence of bilateral
hip replacements; ability to provide self-reported data and informed
consent; planned residence near a field center site for the duration of
the study; and absence of medical conditions judged by the
investigator to result in imminent death. Institutional review boards
at each center approved the study.
From the cohort, random number generators were used to select
1602 men for measurement of sex hormones. Among these, we
excluded 17 (1%) with missing serum estradiol measurement, 94
(6%) with missing serum phosphorus measurements, and 145 (9%)
with missing covariate data, providing a final analytical sample of
1346 subjects for the present analyses.
MrOs Sweden. FGF-23 measurements were considered a key
candidate mediator of the association of sex hormones with serum
phosphorus, and were not available in MrOs US participants.
Therefore, to confirm our findings in an independent cohort, and to
evaluate whether FGF-23 levels attenuated the associations, we
performed a secondary analysis in MrOs Sweden participants—a
sister study to MrOs US participants with a similar design. Study
participants were recruited from three Swedish cities (Malmo,
Goteborg, and Uppsala), identified using national population
registers. Inclusion required male sex, age 69–80 years, and ability
to walk without assistance. Informed consent was obtained from all
study participants.
Among the 3014 MrOs Sweden participants, 375 were excluded
for missing serum estradiol or testosterone measurements, 25 were
excluded for missing serum phosphorus measurements, 30 were
excluded for missing FGF-23 measurements, and 29 were excluded
for other missing covariates, resulting in a study sample of 2555
participants (85%) for this study.
Measurements
Sex hormones. All blood measurements were performed on
venous samples obtained after an overnight fast. Total serum
estradiol and testosterone were measured using a combined tandem
mass spectrometry (Taylor Technology, Princeton, NJ, USA). The
range of detection for estradiol and testosterone were 0.625–80 and
25–3200 pg/ml, and the intra-assay and inter-assay coefficients of
variation (CV) were o7 and o11%, respectively. SHBG was
measured using an Immulite Analyzer with chemiluminescent
substrate (Diagnostic Products Corp., Los Angeles, CA, USA). The
standard curve ranged from 0.2 to 180 nm/l and CVs wereo6%. All
sex hormone and SHBG values were above the respective assay
sensitivities. Serum albumin levels were analyzed using a Roche
COBAS Integra 800 automated analyzer (Roche Diagnostics Corp.,
Indianapolis, IN, USA), with a detectable range from 0.2 to 6.0 g/dl,
and with CV’s o2%. These measurements were combined in
the Sodergard equation31 to calculate bioavailable estradiol and
testosterone levels. Constants used in calculations were 3.14 108 l/
mol for estradiol to SHBG, 4.21 104 l/mol for estradiol to albumin,
5.97 108 l/mol for testosterone to SHBG, and 4.06 104 l/mol for
testosterone to albumin.32
In MrOs Sweden participants, sex hormones were also measured
by mass spectroscopy using a HP5973 quadrupole mass spectro-
meter as described elsewhere.33 For total estradiol, the intra-assay
CV was 1.5% and inter-assay CV was 2.7%, and for total
testosterone the intra-assay CV was 2.9% and inter-assay CV was
3.4%.
Serum phosphorus. In MrOs US participants, serum phos-
phorus measurements were made from morning fasting blood
specimens using a standard clinical automated analyzer (Roche
COBAS Integra 800, Roche Diagnostics) at a central laboratory at
the University of Oregon Health Sciences Center. The range of
detection was 0.3–20.0 mg/dl, all values were within the assay limits,
and CV’s were o3%. In a similar manner, serum phosphorus
measurements were made by a standard clinical chemistry analyzer
in the Department of Clinical Chemistry at the Uppsala University
Hospital in MrOs Sweden, as described elsewhere.34
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Other measurements. Standardized questionnaires provided
information on the participants’ age, race, and history of
hypertension and smoking. Prevalent diabetes was defined by
fasting glucose 4126 mg/dl, use of oral hypoglycemic medications
or insulin, or self-report. Dietary intake of fat, calories, calcium, and
phosphorus were assessed by a modified Block Dietary Data Systems
questionnaire (Block Dietary Data Systems, Berkeley, CA, USA).
Medications were recorded by trained study personnel at the
baseline clinic visit, and were matched to their ingredients based on
the Iowa Drug Information Service (IDIS) Drug Vocabulary
(College of Pharmacy, University of Iowa, Iowa City, IA, USA).35
Height and weight were measured with subjects wearing light
clothes and no shoes, and body mass index was calculated (weight
(kg)/height (m)2). Systolic blood pressure was measured twice at the
right brachial artery using a standard sphygmomanometer and an
8-MHz Doppler probe after a 5-min rest.
Serum calcium, creatinine, alkaline phosphatase, high-density
lipoprotein, total cholesterol, and triglyceride assays were measured
using a Roche COBAS Integra 800 automated analyzer, and low-
density lipoprotein was calculated using the Friedewald equation.36
eGFR was calculated using the modified four-variable Modification
of Diet in Renal Disease equation.37,38 25(OH) vitamin D2 and D3
were measured using liquid chromatography-mass spectrometry,
with deuterated stable isotope 25(OH) vitamin D3 used as the
internal standard. The CVs were o5.0%. The minimum detectable
limit for vitamin D2 is o4 ng/ml and for vitamin D3 is o2 ng/ml.
The sum of vitamin D2 and D3 were used for 25(OH) vitamin D
levels in analyses. Total intact PTH was measured using the
Immunoradiometric Assay 3KG600 (Scantibodies Laboratories
Inc., Santee, CA, USA) with CVs o8.5%.
Whole body BMD was measured using dual energy X-ray
absorptiometry (Hologic, Bedford, MA, USA). A central quality
control lab, certification of dual energy X-ray absorptiometry
operators, and standardized procedures for scanning were used
to insure reproducibility of dual energy X-ray absorptiometry
measurements across field centers. The inter-clinic CVs were 0.6%
for the spine and 0.9% for the hip.
Finally, in MrOs Sweden participants, intact FGF-23 levels were
measured using enzyme-linked immunosorbent assay according to
the manufacturer’s protocol (Kainos Laboratories International,
Tokyo, Japan), as described elsewhere.34,39 The two-site enzyme-
linked immunosorbent assay has previously been shown to
recognize only biologically active FGF-23, and not inactive
C-terminal fragments.
Statistical analysis
We used the MrOs US participants samples for the primary analysis
for this study. Baseline differences in demographical and clinical
variables of the MrOs US participants samples were compared
across phosphorus categories using analysis of variance or
Kruskal–Wallis test for continuous variables, and Chi-squared test
for categorical variables. Graphical methods showed an approximate
Gaussian distribution for serum phosphorus levels, and a linear
relationship between estradiol and phosphorus levels. We used
multivariate linear regression to evaluate the association of total
estradiol as the primary predictor variable of interest, and with
serum phosphorus levels as the dependent variable. An initial model
was unadjusted. Model 1 adjusted for age and race, model 2
additionally adjusted for testosterone, and model 3 additionally
adjusted for SHBG. Model 4 adjusted for other variables selected a
priori based on hypothesized influences on serum phosphorus levels
(eGFR, intact PTH, calcium, and 25(OH) vitamin D). A final model
additionally adjusted for whole body BMD and serum alkaline
phosphatase levels, as we hypothesized that the association of
estradiol with serum phosphorus would be mediated through
changes in urinary phosphorus regulation, and therefore, would
remain independent of BMD and markers of bone turnover. Next,
we evaluated whether results were similar in subjects with or
without CKD (defined as eGFR o60 ml/min per 1.73 m2). These
sequences of models were repeated evaluating serum total
testosterone as the predictor variable of interest. In companion
analyses, we also evaluated the associations of bioavailable estradiol
and testosterone levels with serum phosphorus levels. Next, we
compared the relative strength of association of estradiol and
testosterone with serum phosphorous to the other variables used in
the multivariable models. To facilitate comparison, each was
evaluated as per s.d. change. Skewed variables were natural-log
transformed.
In companion analyses, we replicated the multivariable models
evaluating the association of total estradiol and testosterone with
phosphorus in MrOs Sweden participants. Models were adjusted for
model 4 variables, as described earlier, with two exceptions. All
MrOs Sweden participants were Caucasian, so the race term was
omitted. MrOs Sweden participants came from three Swedish cities,
so a term for city was included to account for potential regional
differences in study participant characteristics.
We used STATA version 9.2 and 10 SE (StataCorp LP,
College Station, TX, USA), and two-tailed Po0.05 were considered
statistically significant for all analyses including interaction terms.
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